Showing 7671-7680 of 10265 results for "".
- Dr. Jennifer Nam Choi Appointed Chief of OncoDermatology for Northwestern Medicinehttps://practicaldermatology.com/news/dr-jennifer-nam-choi-appointed-chief-of-oncodermatology-for-northwestern-medicine/2458809/Jennifer Nam Choi, MD, has been named Chief of the Division of OncoDermatology at Northwestern Memorial Hospital and associate professor in the Department of Dermatology at Northwestern University Feinberg School of Medicine. Dr. Choi is an accomplished dermatologist specializing in the mana
- AMA Calls for Ban on Direct to Consumer Advertising of Prescription Drugs and Medical Deviceshttps://practicaldermatology.com/news/ama-calls-for-ban-on-direct-to-consumer-advertising-of-prescription-drugs-and-medical-devices/2458806/Physicians at the Interim Meeting of the American Medical Association (AMA) adopted new policy aimed at driving solutions to make prescription drugs more affordable. Physicians cited concerns that a growing proliferation of ads is driving demand for expensive treatments despite the clinic
- GSK: Positive Phase 3 Results for Benlysta® In Patients with Systemic Lupus Erythematosushttps://practicaldermatology.com/news/gsk-positive-results-phase-3-results-for-benlysta-in-patients-systemic-lupus-erythematosus/2458812/Results from the BLISS-SC Phase 3 pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) show that Benlysta®(belimumab) 200mg administered weekly via subcutaneous injection plus
- Dermatologist Launches Website For Anti-MOC Campaignhttps://practicaldermatology.com/news/dermatologist-launches-website-for-anti-moc-campaign/2458817/Aimed at dermatologists who “believe that board certification should be a one time right of passage and that Maintenance of Certification (MOC) is an undue burden,” a new website from Las Vegas dermatologist H. L. Greenberg, MD encourages board certified dermatologists to si
- FDA Approves Cotellic Combined with Zelboraf to Treat Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-cotellic-combined-with-zelboraf-to-treat-advanced-melanoma/2458819/The FDA approved Cotellic (cobimetinib) to be used in combination with Zelboraf (vemurafenib) to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation). Cotellic w
- Research Shows Skin Can Reflect Eating Habitshttps://practicaldermatology.com/news/research-shows-skin-can-reflect-eating-habits/2458822/Dermatologists at Baylor College of Medicine say there is evidence that links certain foods to flares in acne. “While there are definitely a number of triggers for acne, the connection between diet and acne is very interesting,” said Dr. Rajani Katta, professor of dermatology
- Lumenis Acquires Pollogen and Expands its Aesthetic Divisionhttps://practicaldermatology.com/news/lumenis-acquires-pollogen-and-expands-its-aesthetic-division/2458827/Lumenis Ltd. completed its acquisition of Pollogen Ltd., an Israeli-based medical aesthetic company that develops and manufactures advanced technologies with full-lines of clinically proven, non-invasive, anti-aging facial and body contouring treatment platforms for a spectrum of aesthetic applic
- Revance Reports Positive 6-Month Duration for RT002 in BELMONT Studyhttps://practicaldermatology.com/news/revance-reports-positive-6-month-duration-for-rt002-in-belmont-study/2458831/Revance Therapeutics, Inc., shared positive 24-week results from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The ongoing study for the treatment of glabellar lines in 268 subjects compared the safety, efficacy, and duration of effect of three doses of RT002
- SecurityMetrics: HIPAA Report Reveals Healthcare's Shortcomingshttps://practicaldermatology.com/news/hipaa-report-reveals-healthcares-shortcomings/2458840/A significant security disparity exists among healthcare c-suite and IT departments, outlined by the SecurityMetrics HIPAA Security Rule Report. In a survey of c-level, risk officers, and IT managers, a 10-20% gap was revealed between what executives believe is happening in regards to patient dat
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</